Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight Therapeutics Announces Health Canada Approval for JORNAY PM(TM) to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

GlobeNewswire 7 days ago

Knight Therapeutics Reports Third Quarter 2024

GlobeNewswire November 7, 2024

Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call

GlobeNewswire October 31, 2024

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

GlobeNewswire October 15, 2024

Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies

GlobeNewswire September 27, 2024

Knight Therapeutics Reports Second Quarter 2024

GlobeNewswire August 8, 2024

Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call

GlobeNewswire August 1, 2024

Knight Announces Normal Course Issuer Bid

GlobeNewswire July 11, 2024

Knight Therapeutics Reports First Quarter 2024 Results

GlobeNewswire May 9, 2024

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America

GlobeNewswire May 9, 2024

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

GlobeNewswire May 8, 2024

Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City

GlobeNewswire May 7, 2024

Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call

GlobeNewswire May 2, 2024

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 9, 2024

Knight Therapeutics Inc. ranks on The Globe and Mail's fifth-annual Women Lead Here benchmark of executive gender diversity

GlobeNewswire March 28, 2024

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

GlobeNewswire March 21, 2024

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

GlobeNewswire March 14, 2024

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

GlobeNewswire February 29, 2024

Knight Therapeutics Inc. Celebrates its First Decade of Success

GlobeNewswire February 28, 2024

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

GlobeNewswire February 21, 2024